Dr. Ivan H. El-Sayed, MD

Dr. El-Sayed practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. El-Sayed's NPI, 1821036419, was assigned on June 3, 2006. Dr. El-Sayed graduated from Boston University School Of Medicine in 1996. Dr. El-Sayed's California license number on file is A79136.

Dr. El-Sayed's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. El-Sayed's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. El-Sayed is also affiliated with Providence Santa Rosa Memorial Hospital. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. El-Sayed to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. El-Sayed practices, 4 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. El-Sayed's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. El-Sayed is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dr. El-Sayed has a license on file in California.

Dmand AI lists chronic sinusitis and endoscopic sinus surgery among the conditions Dr. El-Sayed treats.

CMS data shows 385 Medicare services from Dr. El-Sayed across 8 procedure codes in 2024, for 152 Medicare patients. Medicare paid $26,162 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 152 Medicare patients who saw Dr. El-Sayed in 2024. The largest group is 65 to 74, with 72 patients. 70% of them have high cholesterol, and 69% have high blood pressure. 26% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. El-Sayed's median patient age at 68, with 53% women.

In 2024, Dr. El-Sayed wrote 64 Medicare Part D claims for 30 patients. 100% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $87 in total drug cost. In 2022, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. El-Sayed for performance year 2024, reported as part of a group. Dr. El-Sayed accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. El-Sayed as offering telehealth.

Dmand AI links 136 papers to Dr. El-Sayed, published from 2005 to 2025. 2019 was the busiest year, with 12. The most frequent topics are Carcinoma, Squamous Cell, Endoscopy and Gold. Dr. El-Sayed has published most often in World Neurosurg. Dr. El-Sayed's most frequent co-authors are Manish Kumar Aghi, MD, PhD, William Russell Ryan, MD and Adib Adnan Abla, MD.

CMS Open Payments shows 28 general payments to Dr. El-Sayed from 9 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 74% of the total. Stryker Corporation paid the most, $1,366.

Dmand AI lists 4 awards for Dr. El-Sayed, most recently Regional Top Doctor in 2014.

Dr. El-Sayed graduated from Boston University School Of Medicine in 1996. Dr. El-Sayed is a member of NHS, ACS and North American Skull Base Society.

Dr. El-Sayed is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.